Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

NCT02345070 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

327

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: SAR156597
DRUG: placebo

Sponsor

Sanofi